propan-2-yloxyphosphinate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: propan-2-yloxyphosphinate
• 化学式: C3H8O3P-
• 分子量: 123.07
• InChiKey: JGFMNFBZRAISGQ-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  49.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  四氢呋喃 、 propan-2-yloxyphosphinate 、 正丁基锂 、 methyl 3-[dimethoxy(phenyl)methyl]benzoate 在 碳酸氢钠 、 magnesium sulfate 作用下， 以 hexanes 、 乙酸乙酯 为溶剂， 反应 1.92h， 生成 {2-[3-(dimethoxy-phenyl-methyl)-phenyl]-2-oxo-ethyl}-phosphonic acid dimethyl ester
  参考文献：
  名称：

  8-aza-11-deoxy prostaglandin analogues

  摘要：

  本发明涉及一类化合物，通常是EP4受体激动剂，其由式I表示：其中A是—CH2—CH2—或—CH═CH—；B是缺失的、芳基或杂芳基基团；当B为芳基或杂芳基且R3、R4、R5和R6不同时为氢时，R1是烷基、烯基、炔基、环烷基烷基、杂环基烷基、芳基、芳基烷基或杂芳基；当B缺失且R3、R4、R5和R6同时为氢时，R1是杂环基烷基、芳基或杂芳基；其他取代基如说明书中定义；或其单个异构体、外消旋或非外消旋异构体混合物或药学上可接受的盐或溶剂。本发明还涉及包含这些化合物的药物组合物、它们作为治疗剂的使用方法以及制备它们的方法。

  公开号：

  US06900336B2

文献信息

• 8-Aza-11-deoxy prostaglandin analogues
  申请人：——

  公开号：US20030120079A1

  公开（公告）日：2003-06-26

  This invention relates to compounds which are generally EP 4 receptor agonists and which are represented by Formula I: 1 wherein A is a —CH 2 —CH 2 —, or —CH═CH—; B is absent, an aryl, or heteroaryl group; R 1 is alkyl, alkenyl, alkynyl, cycloalkylalkyl, heterocyclylalkyl, aryl, arylalkyl or heteroaryl, when B is aryl or heteroaryl and R 3 , R 4 , R 5 and R 6 are not simultaneously hydrogen, or R 1 is heterocyclylalkyl, aryl, or heteroaryl when B is absent and R 3 , R 4 , R 5 and R 6 are simultaneously hydrogen; and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

  本发明涉及一般为EP4受体激动剂的化合物，其由式I表示：1其中，A是—CH2—CH2—或—CH═CH—；B是缺失、芳基或杂芳基基团；当B为芳基或杂芳基时，R1为烷基、烯基、炔基、环烷基烷基、杂环基烷基、芳基、芳基烷基或杂芳基；或当B缺失且R3、R4、R5和R6同时为氢时，R1为杂环基烷基、芳基或杂芳基；其他取代基如规范中所定义；或其单个异构体、外消旋或非外消旋异构体混合物，或其药学上可接受的盐或溶剂物。本发明还涉及含有这种化合物的制药组合物，以及它们作为治疗剂的使用方法和制备方法。
• Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
  申请人：SciFluor Life Sciences, LLC

  公开号：US08901144B2

  公开（公告）日：2014-12-02

  The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described.

  该发明涉及氟化合物及其作为整合素受体拮抗剂的用途。描述了新型氟化的3-(2-氧代-3-(3-芳基丙基)咪唑啉-1-基)-3-芳基丙酸衍生物及其制备的药学上可接受的盐或溶剂，以及它们的用途。
• Fluorinated 3-(2-Oxo-3-(3-Arylpropyl)Imidazolidin-1-yl)-3-Arylpropanoic Acid Derivatives
  申请人：SciFluor Life Sciences, LLC

  公开号：US20150057308A1

  公开（公告）日：2015-02-26

  The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3 -arylpropyl)imidazolidin-1-yl)-3 -arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described.

  本发明涉及氟化合物及其用作整合素受体拮抗剂。描述了新型氟化3-（2-氧代-3-（3-芳基丙基）咪唑啉-1-基）-3-芳基丙酸衍生物及其药学上可接受的盐或溶剂，以及它们的用途。
• FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF
  申请人：SciFluor Life Sciences, Inc.

  公开号：US20160244447A1

  公开（公告）日：2016-08-25

  The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及式I的氟化合物及其合成方法。本发明还涉及包含本发明中的氟化合物的制药组合物，以及通过将这些化合物和制药组合物用于需要治疗纤维化、黄斑退化、糖尿病视网膜病变（DR）、黄斑水肿、糖尿病性黄斑水肿（DME）和视网膜静脉阻塞后的黄斑水肿（RVO）的患者来进行治疗的方法。
• FLUORINATED INTEGRIN ANTAGONISTS
  申请人：SCIFLUOR LIFE SCIENCES, INC.

  公开号：US20160075698A1

  公开（公告）日：2016-03-17

  The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及式I的氟化合物及其合成方法。本发明还涉及含有本发明的氟化合物的药物组合物，并通过将这些化合物和药物组合物给予需要治疗黄斑变性、糖尿病视网膜病变（DR）、黄斑水肿、糖尿病性黄斑水肿（DME）和视网膜静脉阻塞后的黄斑水肿（RVO）的受试者来治疗这些疾病。